IgHV5-51: A Protein with Potential as A Drug Target and Biomarker

Target Name: IGHV5-51

NCBI ID: G28388

IGHV5-51

Other Name(s): immunoglobulin heavy variable 5-51 | Immunoglobulin heavy variable 5-51 | VH | IGHV551

IgHV5-51: A Protein with Potential as A Drug Target and Biomarker

IGHV5-51, also known as immunoglobulin heavy variable 5-51 (IgHV5-51), is a type of protein that is expressed in the B cells of the human body. It is a part of the immunoglobulin family, which is a group of proteins that are responsible for the development and function of antibodies. IgHV5-51 is one of the proteins within this family and is expressed in the majority of B cells.

IgHV5-51 plays a crucial role in the immune response. It is one of the proteins that is involved in the development of antibodies, which are proteins that are produced by B cells in response to the presence of foreign substances in the body. IgHV5-51 helps to regulate the production and diversity of antibodies, ensuring that the immune system is able to effectively respond to a wide range of threats.

One of the key benefits of IgHV5-51 is its potential as a drug target. Its unique structure and function make it an attractive target for researchers to study and potentially develop into a treatment for a variety of diseases. For example, IgHV5-51 has been shown to be involved in the development of autoimmune diseases, such as rheumatoid arthritis and lupus. By targeting this protein, researchers may be able to develop new treatments that specifically target these diseases and reduce the risk of side effects.

Another potential use for IgHV5-51 is as a biomarker for cancer. Its expression has been observed in a variety of cancer types, including breast, ovarian, and colorectal cancer. This suggests that it may be a useful indicator of the spread of these diseases and could be used to track the effectiveness of different treatments.

IgHV5-51 has also been shown to play a role in the regulation of inflammation. Its presence has been associated with the production of pro-inflammatory cytokines, which can contribute to the development of inflammatory diseases. By targeting this protein, researchers may be able to develop new treatments for a variety of inflammatory diseases.

In addition to its potential as a drug target and biomarker, IgHV5-51 is also of interest to researchers because of its unique structure and function. Its protein sequence is highly conserved across different species, which suggests that it has been evolutionary conserved over time. This suggests that it may have a similar function across different species, which could make it a useful starting point for the development of new treatments.

Overall, IgHV5-51 is a protein that holds great promise as a drug target and biomarker. Its unique structure and function make it an attractive target for researchers to study and develop new treatments for a variety of diseases. Further research is needed to fully understand its role in the immune response and its potential as a treatment.

Protein Name: Immunoglobulin Heavy Variable 5-51

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV5-51 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV5-51 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets